within Pharmacolibrary.Drugs.ATC.A;

model A03AX08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.24,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Alverine is an antispasmodic drug used primarily for the symptomatic treatment of irritable bowel syndrome (IBS) and other conditions involving smooth muscle spasm in the gastrointestinal tract. It is not approved by the FDA in the United States but is available in some European and other countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for alverine in healthy adults; no peer-reviewed literature providing detailed PK modeling found.</p><h4>References</h4><ol><li><p>Ghosh, C, et al., &amp; Chakraborty, BS (2010). A rapid and most sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of alverine and its major metabolite, para hydroxy alverine, in human plasma: application to a pharmacokinetic and bioequivalence study. <i>Drug testing and analysis</i> 2(6) 284â€“291. DOI:<a href=&quot;https://doi.org/10.1002/dta.130&quot;>10.1002/dta.130</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20564607/&quot;>https://pubmed.ncbi.nlm.nih.gov/20564607</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03AX08;
